NZ624493B2 - Ultra-concentrated rapid-acting insulin analogue formulations - Google Patents
Ultra-concentrated rapid-acting insulin analogue formulations Download PDFInfo
- Publication number
- NZ624493B2 NZ624493B2 NZ624493A NZ62449312A NZ624493B2 NZ 624493 B2 NZ624493 B2 NZ 624493B2 NZ 624493 A NZ624493 A NZ 624493A NZ 62449312 A NZ62449312 A NZ 62449312A NZ 624493 B2 NZ624493 B2 NZ 624493B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- insulin
- acid
- analogue
- substitution
- chain
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 614
- 239000004026 insulin derivative Substances 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 108010026951 Short-Acting Insulin Proteins 0.000 title description 5
- 108090001061 Insulin Proteins 0.000 claims abstract description 235
- 102000004877 Insulin Human genes 0.000 claims abstract description 234
- 238000006467 substitution reaction Methods 0.000 claims abstract description 108
- 150000001413 amino acids Chemical class 0.000 claims abstract description 37
- 229920001184 polypeptide Polymers 0.000 claims abstract description 37
- 238000009472 formulation Methods 0.000 claims abstract description 31
- 210000004369 Blood Anatomy 0.000 claims abstract description 17
- 230000002378 acidificating Effects 0.000 claims abstract description 17
- 239000008280 blood Substances 0.000 claims abstract description 17
- 239000011780 sodium chloride Substances 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 108010076181 Proinsulin Proteins 0.000 claims abstract description 8
- 101800000896 Insulin B chain Proteins 0.000 claims abstract description 5
- 102400000454 Insulin B chain Human genes 0.000 claims abstract description 5
- 235000001014 amino acid Nutrition 0.000 claims description 47
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 24
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 17
- 229960002989 Glutamic Acid Drugs 0.000 claims description 12
- 235000013922 glutamic acid Nutrition 0.000 claims description 12
- 239000004220 glutamic acid Substances 0.000 claims description 12
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 11
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 9
- 229960003104 Ornithine Drugs 0.000 claims description 9
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 claims description 8
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine zwitterion Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 8
- 229960003692 aminobutyric acid Drugs 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 7
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 7
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N DL-alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 6
- -1 Omithine Chemical compound 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 229960005261 Aspartic Acid Drugs 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- 229960003767 Alanine Drugs 0.000 claims description 3
- 101800001819 Insulin A chain Proteins 0.000 claims description 3
- 102400000453 Insulin A chain Human genes 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 239000011701 zinc Substances 0.000 abstract description 14
- 229910052725 zinc Inorganic materials 0.000 abstract description 13
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 12
- VYRYMCNWIVZAGH-QMMMGPOBSA-N (2S)-2-(fluoroamino)-3-phenylpropanoic acid Chemical group OC(=O)[C@@H](NF)CC1=CC=CC=C1 VYRYMCNWIVZAGH-QMMMGPOBSA-N 0.000 abstract description 2
- 230000027455 binding Effects 0.000 description 38
- 230000003285 pharmacodynamic Effects 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 23
- 102000005962 receptors Human genes 0.000 description 23
- 108020003175 receptors Proteins 0.000 description 23
- 206010012601 Diabetes mellitus Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 230000004048 modification Effects 0.000 description 22
- 238000006011 modification reaction Methods 0.000 description 22
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 20
- 125000003118 aryl group Chemical group 0.000 description 20
- 230000000275 pharmacokinetic Effects 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
- 210000004027 cells Anatomy 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 16
- 239000000178 monomer Substances 0.000 description 15
- WNRQPCUGRUFHED-DETKDSODSA-N Humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 14
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 14
- 102100014263 IGF1R Human genes 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 206010061592 Cardiac fibrillation Diseases 0.000 description 13
- 230000002600 fibrillogenic Effects 0.000 description 13
- 108020004705 Codon Proteins 0.000 description 12
- 102100014231 IGF1 Human genes 0.000 description 12
- 229960005190 Phenylalanine Drugs 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000000539 dimer Substances 0.000 description 12
- 238000004166 bioassay Methods 0.000 description 11
- 230000001965 increased Effects 0.000 description 11
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 238000005755 formation reaction Methods 0.000 description 10
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- PTFCDOFLOPIGGS-UHFFFAOYSA-N zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 9
- 229940103471 Humulin Drugs 0.000 description 8
- 108010065920 Insulin Lispro Proteins 0.000 description 8
- 229960002068 Insulin Lispro Drugs 0.000 description 8
- 102000003746 Insulin Receptor Human genes 0.000 description 8
- 108010001127 Insulin Receptor Proteins 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000036961 partial Effects 0.000 description 8
- 230000036515 potency Effects 0.000 description 8
- 238000010254 subcutaneous injection Methods 0.000 description 8
- 239000007929 subcutaneous injection Substances 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 240000003550 Eusideroxylon zwageri Species 0.000 description 7
- 241000282887 Suidae Species 0.000 description 7
- 238000002983 circular dichroism Methods 0.000 description 7
- 230000002209 hydrophobic Effects 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 238000001338 self-assembly Methods 0.000 description 7
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 6
- 229940038661 Humalog Drugs 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- 230000035832 Lag time Effects 0.000 description 6
- 230000035648 Lag-time Effects 0.000 description 6
- 230000035578 autophosphorylation Effects 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 229940088597 Hormone Drugs 0.000 description 5
- 206010022489 Insulin resistance Diseases 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 230000002641 glycemic Effects 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000036947 Dissociation constant Effects 0.000 description 4
- 108010073961 Insulin Aspart Proteins 0.000 description 4
- VOMXSOIBEJBQNF-UTTRGDHVSA-N NovoRapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 4
- 229920001850 Nucleic acid sequence Polymers 0.000 description 4
- 229940035295 Ting Drugs 0.000 description 4
- 230000003942 amyloidogenic Effects 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 238000005421 electrostatic potential Methods 0.000 description 4
- 230000002708 enhancing Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229960004717 insulin aspart Drugs 0.000 description 4
- 230000001404 mediated Effects 0.000 description 4
- 230000002297 mitogenic Effects 0.000 description 4
- 230000001264 neutralization Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 230000036231 pharmacokinetics Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002035 prolonged Effects 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- RCHHVVGSTHAVPF-ZPHPLDECSA-N Apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 3
- LEMUFSYUPGXXCM-JNEQYSBXSA-N Caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 3
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 229920002892 amber Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000002144 chemical decomposition reaction Methods 0.000 description 3
- 229910052803 cobalt Inorganic materials 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- 229910001429 cobalt ion Inorganic materials 0.000 description 3
- 230000002860 competitive Effects 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000002349 favourable Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000001603 reducing Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 2
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 2
- 229960001334 Corticosteroids Drugs 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- COCFEDIXXNGUNL-RFKWWTKHSA-N Glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 2
- 229940084769 Humulin R Drugs 0.000 description 2
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 2
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 229940060975 Lantus Drugs 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229960001052 Streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000004308 accommodation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000069 breast epithelial cell Anatomy 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000003508 chemical denaturation Methods 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 102000034327 globular proteins Human genes 0.000 description 2
- 108091005889 globular proteins Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002218 hypoglycaemic Effects 0.000 description 2
- 230000001771 impaired Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960000696 insulin glulisine Drugs 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229940100630 metacresol Drugs 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002922 simulated annealing Methods 0.000 description 2
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000087 stabilizing Effects 0.000 description 2
- 230000004936 stimulating Effects 0.000 description 2
- 125000004434 sulfur atoms Chemical group 0.000 description 2
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 2
- 239000000700 tracer Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 230000000381 tumorigenic Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DEQANNDTNATYII-MEUDYGGUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)NC(CO)C(O)C)C1=CC=CC=C1 DEQANNDTNATYII-MEUDYGGUSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N 1,4-Butanediol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- SLVOVFVZZFUEAS-UHFFFAOYSA-N 2-[2-[2-[bis(carboxymethyl)amino]ethoxy]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCN(CC(O)=O)CC(O)=O SLVOVFVZZFUEAS-UHFFFAOYSA-N 0.000 description 1
- LMWMTSCFTPQVCJ-UHFFFAOYSA-N 2-methylphenol;phenol Chemical compound OC1=CC=CC=C1.CC1=CC=CC=C1O LMWMTSCFTPQVCJ-UHFFFAOYSA-N 0.000 description 1
- PMLGQXIKBPFHJZ-UHFFFAOYSA-N 3-aminobutane-1,2,4-triol Chemical compound OCC(N)C(O)CO PMLGQXIKBPFHJZ-UHFFFAOYSA-N 0.000 description 1
- 101710034857 ATIC Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940112930 Apidra Drugs 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N Bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000220450 Cajanus cajan Species 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L Calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011652 Cushing's syndrome Diseases 0.000 description 1
- 229960003067 Cystine Drugs 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000008745 EC 6.1.1.- Human genes 0.000 description 1
- 108030004302 EC 6.1.1.- Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 210000000474 Heel Anatomy 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020993 Hypoglycaemia Diseases 0.000 description 1
- 101700049319 INS Proteins 0.000 description 1
- 101000187184 INSR Proteins 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- 241001527806 Iti Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 125000002068 L-phenylalanino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 101700027927 LLPH Proteins 0.000 description 1
- 108010077977 Lente Insulin Proteins 0.000 description 1
- 206010024606 Lipodystrophy Diseases 0.000 description 1
- 208000006132 Lipodystrophy Diseases 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 229920000460 Mitochondrial DNA Polymers 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 description 1
- 229920002649 Nonsense suppressor Polymers 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 229960002700 Octreotide Drugs 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 229960001494 Octreotide Acetate Drugs 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010026080 Somatomedins Proteins 0.000 description 1
- 229940052907 Telazol Drugs 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 1
- 108009000112 Type II diabetes mellitus Proteins 0.000 description 1
- 108010061168 Ultralente Insulin Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- DJWUNCQRNNEAKC-UHFFFAOYSA-L Zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 230000001800 adrenalinergic Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 201000004569 blindness Diseases 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000003857 carboxamides Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000001610 euglycemic Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000034561 human INSR protein Human genes 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 108010044655 lysylproline Proteins 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- 230000000291 postprandial Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 108010000947 protamine zinc Proteins 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005469 synchrotron radiation Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavin T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 1
- QAXBVGVYDCAVLV-UHFFFAOYSA-N tiletamine Chemical compound C=1C=CSC=1C1(NCC)CCCCC1=O QAXBVGVYDCAVLV-UHFFFAOYSA-N 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
Abstract
pharmaceutical formulation comprises insulin having a variant insulin B-chain polypeptide containing an monofluoro-Phenylalanine substitution at position B24 in combination with a substitution of an amino acid containing an acidic side chain at position B10, allowing the insulin to be present at a concentration of between 0.6 mM and 3.0 mM. The formulation may optionally be devoid of zinc. Amino-acid substitutions at one or more of positions B3, B28, and B29 may additionally be present. The variant B-chain polypeptide may be a portion of a proinsulin analogue or single-chain insulin analogue. The insulin analogue may be an analogue of a mammalian insulin, such as human insulin. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to the patient. concentration of between 0.6 mM and 3.0 mM. The formulation may optionally be devoid of zinc. Amino-acid substitutions at one or more of positions B3, B28, and B29 may additionally be present. The variant B-chain polypeptide may be a portion of a proinsulin analogue or single-chain insulin analogue. The insulin analogue may be an analogue of a mammalian insulin, such as human insulin. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to the patient.
Description
ULTRA—CONCENTRATED RAPID-ACTING INSULIN ANALOGUE
FORMULATIONS
ENT REGARDING LLY SPONSORED
CH OR DEVELOPMENT
This invention was made with government suppon under cooperative agreements
awarded by the National Institutes of Health under grant numbers DK40949 and DK074176.
The US. government may have certain rights to the invention.
BACKGROUND OF THE INVENTION
This invention relates to polypeptide hormone analogues that exhibit enhanced
pharmaceutical properties, such as more rapid pharmacokinetics at polypeptide concentrations
greater than are ordinarily employed in pharmaceutical ations. This invention also relates
to n analogues that are modified by the incorporation of non-standard amino acids to enable
their formulation at concentrations higher than 100 units per ml (U-100) such that (i) rapid-acting
pharmacokinetic (PK) and pharmacodynamic (PD) properties are retained relative to ype
human insulin at a U-lOO concentration and such that (ii) their mitogenic properties are not
elevated relative to wild-type human insulin. Such non-standard sequences may optionally
contain rd acid substitutions at other sites in the A or B chains of an insulin
analogue.
The engineering of non—standard proteins, including therapeutic agents and vaccines,
may have broad medical and societal benefits. An e of a medical benefit would be
zation of the pharmacokinetic properties of a protein. An example of a further societal
benefit would be the ering of proteins amenable to formulation at high protein
trations with deterioration of the PK/PD properties of the formulation. An example of a
therapeutic protein is provided by insulin. Analogues of insulin containing non—standard amino—
acid substitutions may in principle exhibit superior properties with respect to PK/PD or the
dependence of PK/PD on the concentration of n in the ation. The challenge posed
by the pharmacokinetics of insulin absorption following subcutaneous injection affects the
ability of patients with diabetes mellitus (DM) to achieve tight glycemic control and constrains
the safety and performance ofinsulin pumps.
A particular l need is posed by the marked resistance to insulin exhibited by
certain patients with DM associated with obesity, by certain patients with DM associated with a
genetic predisposition to insulin resistance, and by patients with DM secondary to lipodystrophy,
treatment with corticosteroids, or over-secretion of endogenous corticosteroids (Cushing’s
Syndrome). The number of patients with marked insulin resistance is growing due to the obesity
ic in the developed and developing worlds (leading to the syndrome of “diabesity”) and
due to the increasing recognition of a monogenic form of DM arising from a mutation in
mitochondrial DNA in which insulin resistance can be unusually severe (van den Ouweland,
J.M., Lemkes, H.H., Ruitenbeek, W., Sandkuijl, L.A., de Vijlder, M.F., Struyvenberg, P.A., van
de Kamp, J.J., & Maassen, J.A. (1992) Mutation in ondrial eu)(UUR) gene in a
large pedigree with ally itted type II diabetes mellitus and deafness. Nature Genet.
1, 368-71). Treatment of such otherwise diverse subsets of patients typically requires the
subcutaneous injection of large volumes of regular insulin formulations (U-lOO strength;
ordinarily 0.6 mM insulin or insulin analogue). Injection of such large s can lead to pain
and variability in the rate of onset and duration of insulin . Although a U-SOO ation
of wild-type insulin is ble for clinical use (Humulin® R U-500; Eli Lilly and Co.), the
se in insulin tration from 0.6 mM to 3 mM leads to a delay in the onset, and
prolongation, of insulin action such that the PK/PD properties of Humulin® R U-500, or similar
such products, resemble those of a micro-crystalline sion of protamine-zinc-containing
insulin hexamers; this formulation has long been designated neutral ine Hagadom (NPH).
Prandial use of a U-SOO formulation of wild-type insulin by subcutaneous injection would thus
be expected to decrease the efficacy of glycemic control and se the risk of hypoglycemic
episodes. Use of Humulin® R U-500, or similar such products in a device for continuous
subcutaneous insulin infusion (CSIl; an “insulin pump”) would likewise be expected to interfere
with the ability of the patient or l algorithm to make effective adjustments in insulin
infusion rates based on current or past measurements of blood glucose concentrations, leading to
suboptimal glycemic control and increased risk of hypoglycemic events.
A well-established principle of insulin pharmacology relates the aggregation state of
the injected insulin molecule to the time course of tion from the depot into capillaries and
hence into the systemic circulation. In general the more aggregated are the insulin molecules
into high-molecular weight complexes, the greater the delay in absorption and more ged
the insulin action. Amino-acid substitutions in the insulin molecule that weaken its self-
assembly are known in the art to be associated with more rapid absorption relative to wild-type
human insulin; examples are provided by the substitution ProBngi Asp (insulin aspart, the active
ent of Novolog®; Novo-Nordisk, Ltd) and by the paired substitutions Prostfi Lys and
LysB2911 Pro (insulin Lispro, the active component of Humalog®; Eli Lilly and Co.). sely,
amino—acid extensions or chemical modifications of the insulin le that cause a shift in its
isoelectric point (pl) from ca. pH 5 to ca. pH 7 are known in the art to lead to isoelectric
precipitation of the modified n in the subcutaneous depot; such high molecular—weight
complexes provide prolonged absorption as a basal insulin formulation. Examples are provided
by NovoSol Basal® (a discontinued product of Novo-Nordisk in which 7 was substituted by
Arg and in which the C-terminal ylate moiety of Thr1330 was amidated) and insulin
glargz'ne (the active component of Lantus®, a basal formulation in which the B chain was
extended by the dipeptide ArgB3l-ArgB32; Sanofi-Aventis, Ltd.). (NovoSol Basal® and Lantus®
each contain the additional substitution fi Gly to enable their soluble formulation under
acidic conditions (pH 3 and pH 4 respectively) without chemical degradation due to deamidation
of AsnAZl.) Prolongation of cal micro-crystalline insulin suspensions (NPH, semi-lente,
lente, and ultra-lente) exhibit a range of intermediate-to-long—acting PK/PD properties reflecting
the respective o-chemical properties of these micro-crystals and their ve rates of
dissolution.
The above insulin products, including current and past formulations of wild-type
human insulin or animal insulins, employ or employed self-assembly of the insulin molecule as a
means to achieve chemical stability, as a means to avoid fibril formation, as a means to modulate
PK/PD properties, or as a means to achieve a ation of these objectives. Yet insulin self-
assembly can also introduce unfavorable 0r undesired properties. The non-optimal prolonged
PK/PD properties of Humulin® R U-500 (or a similar such product), for example, are likely to be
the result of hexamer-hexamer ations in the formulation and in the subcutaneous depot.
Indeed, studies of wild-type bovine insulin zinc hexamers in Vitro by laser light scattering have
provided evidence of ssive hexamer—hexamer interactions in the tration range 0.3—3
mM. Current and past strategies for the composition of insulin formulations and design of
insulin analogues therefore face and have faced an irreconcilable barrier to the development of a
rapid-acting ultra-concentrated insulin formulation: whereas self-assembly is necessary to obtain
chemical and physical ity, its progressive nature above 0.6 mM leads to unfavorable
prolongation of PK/PD.
During the past decade specific chemical modifications to the insulin molecule have
been described that selectively modify one or r particular property of the protein to
facilitate an application of interest. Whereas at the beginning of the recombinant DNA era
(1980) wild—type human insulin was envisaged as being l for use in diverse therapeutic
contexts, the broad clinical use of insulin analogues in the past decade suggests that a suite of
non-standard analogs, each tailored to address a c unmet need, would provide significant
medical and societal benefits. Substitution of one natural amino acid at a specific position in a
protein by another natural amino acid is well known in the art and is herein designated a standard
substitution. Non—standard substitutions in insulin offer the prospect of rated absorption
without worsening of PIUPD as a function of insulin analogue concentration in the range 0.6 —
3.0 mM.
Administration of insulin has long been established as a treatment for diabetes
mellitus. Insulin is a small globular protein that plays a central role in lism in vertebrates.
Insulin contains two chains, an A chain, containing 21 residues, and a B chain containing 30
residues. The hormone is stored in the atic b-cell as a Zn2+-stabilized hexamer, but
functions as a Zn2+-free monomer in the bloodstream. Insulin is the t of a single-chain
precursor, proinsulin, in which a connecting region (35 residues) links the C-terminal residue of
B chain ue B30) to the inal residue of the A chain. lline arrays of zinc insulin
hexamers within mature storage granules have been ized by electron microscopy (EM).
The sequence of insulin is shown in schematic form in Figure 1. Individual residues are indicated
by the identity of the amino acid (typically using a standard three—letter code), the chain and
sequence position (typically as a superscript).
Aromatic side chains in n, as in globular proteins in general, may engage in a
variety of hydrophobic and weakly polar interactions, involving not only oring aromatic
rings but also other sources of positive- or negative electrostatic potential. Examples e
main—chain carbonyl- and amide groups in peptide bonds. Hydrophobic packing of aromatic side
chains is believed to occur within the core of proteins and at non-polar interfaces between
proteins. Such aromatic side chains can be conserved among rate ns, reflecting their
key contributions to structure or function. An example of a natural aromatic amino acid is
alanine. Its aromatic ring system contains six carbons arranged as a planar hexagon.
Aromaticity is a collective property of the binding arrangement among these six carbons, g
to p electronic ls above and below the plane of the ring. These faces t a partial
negative electrostatic potential whereas the edge of the ring, containing five C-H moieties,
exhibits a partial positive electrostatic potential. This asymmetric distribution of partial charges
gives rise to a quadrapole electrostatic moment and may participate in weakly polar interactions
with other formal or partial charges in a n. An additional characteristic feature of an
aromatic side chains is its volume. Determinants of this volume include the topographic
contours of its five C—H moieties at the edges of the planar ring. Substitution of one C—H moiety
by a GP moiety would be expected to preserve its aromaticity but introduced a significant dipole
moment in the ring due to the electronegativity of the fluorine atom and consequent distortion of
the p electronic orbitals above and below the plane of the ring. Whereas the size of the C-F
moiety is similar to that of the native C—H moiety (and so could in principle be accommodated in
diverse protein environments), its local onegativity and ring-specific fluorine-induced
ostatic dipole moment could introduce favorable or unfavorable electrostatic interactions
with neighboring groups in a protein. Examples of such neighboring groups include, but are not
cted to, CO-NH e bond units, lone pair electrons of sulfur atoms in disulfide bridges,
side-chain carboxamide functions (Asn and Gln), other aromatic rings (Phe, Tyr, Trp, and His),
and the formal positive and ve charges of acidic side chains (Asp and Glu), basic side
chains (Lys and Arg), a titratable side chain with potential pKa in the range used in insulin
formations (His), titratable N— and C-terminal chain termini, bound metal ions (such as Zn2+ or
Ca2+), and protein-bound water molecules.
An example of a conserved aromatic residue in a therapeutic protein is ed by
phenylalanine at position B24 of the B chain ofinsulin (designated Phe ). This is one of three
phenylalanine residues in insulin (positions Bl, B24, and B25). A structurally similar tyrosine is
824 -
at position B26. The structural environment of Phe 1n an insulin monomer is shown in a
ribbon model (Fig. 2A) and in a filling model (Fig. 2B). Conserved among vertebrate
insulins and insulin—like growth factors, the aromatic ring of Phe1324 packs against (but not
within) the hydrophobic core to stabilize the super-secondary structure of the B chain. Phe!324
lies at the classical receptor-binding surface and has been proposed to direct a change in
mation on receptor binding. Phe1324 packs at the dimer interface of insulin and so at three
interfaces of an insulin hexamer. Its structural environment in the insulin r differs from
its structural environment at these interfaces. In particular, the surrounding volume available to
the side chain of PheB24 is larger in the monomer than in the dimer or hexamer.
A major goal of insulin replacement therapy in patients with DM is tight control of
the blood glucose tration to prevent its excursion above or below the normal range
characteristic of healthy human subjects. Excursions below the normal range are associated with
immediate adrenergic or neuroglycopenic symptoms, which in severe episodes lead to
convulsions, coma, and death. Excursions above the normal range are associated with increased
long—term risk of microvascular e, including pathy, blindness, and renal failure.
Because the pharmacokinetics of absorption of wild-type human insulin or human insulin
analogues—when formulated at strengths greater than U—lOO—is often too slow, too prolonged
and too variable relative to the physiological requirements of randial lic
homeostasis, patients with DM associated with marked insulin resistance often fail to achieve
optimal glycemic targets and are thus at increased risk of both immediate and long—term
complications. Thus, the safety, efficacy, and real-world convenience of regular and rapid-acting
insulin products have been limited by prolongation of PK/PD as the concentration of self-
assembled insulin or insulin analogue is made higher than ca. 0.6 mM.
The present invention circumvents the necessity for insulin self-assembly as a
mechanism to achieve a formulation of sufficient chemical stability and of sufficient physical
stability to meet or exceed regulatory standards. Chemical degradation refers to changes in the
arrangement of atoms in the insulin molecule, such as deamidation of Asn, formation of iso-Asp,
and breakage of disulfide bridges. The susceptibility of n to al degradation is
correlated with its thermodynamic stability (as probed by chemical denaturation experiments);
because it is the monomer that is the species most tible to chemical degradation, its rate is
d by sequestration of monomers within self-assemblies. al degradation refers to
fibril formation llation), which is a non-native form of self-assembly that leads to linear
structures containing thousands (or more) of insulin protomers in a beta-sheet rich conformation.
lation is a serious concern in the manufacture, storage and use of insulin and insulin
analogues above room temperature. Rates of fibrillation are enhanced with higher temperature,
lower pH, agitation, or the presence of urea, guanidine, ethanol co-solvent, or hydrophobic
surfaces. Current US drug tions demand that insulin be discarded if fibrillation occurs at a
level of one percent or more. Because fibrillation is enhanced at higher temperatures, patients
with DM optimally rrrust keep insulin refrigerated prior to use. Fibrillation of insulin or an
insulin ue can be a particular concern for such patients utilizing an external n pump,
in which small amounts of insulin or insulin analogue are injected into the patient’s body at
regular intervals. In such a usage, the insulin or insulin analogue is not kept refrigerated within
the pump apparatus, and fibrillation of n can result in blockage of the catheter used to inject
n or insulin analogue into the body, potentially resulting in ictable fluctuations in
blood glucose levels or even dangerous hyperglycemia. At least one recent report has indicated
that insulin Lispro (KP—insulin, an analogue in which residues B28 and B29 are interchanged
relative to their positions in wild-type human insulin; trade name Humalog®) may be ularly
susceptible to fibrillation and resulting obstruction of insulin pump catheters. Insulin exhibits an
se in degradation rate of 10-fold or more for each 10° C increment in temperature above
° C; accordingly, guidelines call for storage at temperatures < 30° C and preferably with
refrigeration. Such formulations typically include a predominance of native insulin self-
assemblies.
The present theory of protein fibrillation posits that the mechanism of fibrillation
proceeds via a partially folded intermediate state, which in turn aggregates to form an
amyloidogenic nucleus. In this theory, it is possible that amino—acid substitutions that stabilize
the native state may or may not stabilize the lly folded intermediate state and may or may
not increase (or decrease) the free-energy barrier n the native state and the intermediate
state. Therefore, the current theory indicates that the tendency of a given amino—acid substitution
in the insulin molecule to increase or decrease the risk of ation is highly ictable; in
particular the lag time observed prior to onset of detectable ation does not ate with
ements of the thermodynamic stability of the native-state monomer (as probed by
chemical ration experiments). Whereas a given substitution may stabilize both the overall
native state and amyloidogenic partial fold—and so delay the onset of fibrillation—another
substitution may stabilize the native state but not the amyloidogenic partial fold and so have little
or no effect on the lag time. Still other substitutions may destabilize the native state but stabilize
the amyloidogenic partial fold, and so lead to accelerated fibrillation despite its apparent
stabilizing properties.
There is a need, therefore for an insulin ue that displays rapid PK/PD for the
treatment of DM under a broad range of insulin concentrations from 0.6 mM to 3.0 mM
(typically corresponding to formulation strengths in a range from U-lOO to U—500) while
ting at least a portion of the activity of the corresponding wild-type insulin, ining at
least a portion of its chemical and/or al stability.
SUMMARY OF THE INVENTION
It is an aspect of the present invention to provide insulin ues that provide zinc-
free monomeric and dimeric species of ent chemical stability and physical stability to
enable their formulation at a range of protein concentrations and in a form that confers rapid
absorption following subcutaneous injection. The present invention addresses previous
limitations for ultra-concentrated insulin formulations and insulin analogues formulations,
namely, that they still do not act sufficiently quickly to optimize post-prandial glycemic control
or enable use in insulin pumps. The claimed ion circumvents previous design restrictions,
including those regarding substitution of PheB24, through the incorporation of a non-standard
amino-acid substitution at position B24. The non-standard amino-acid side chain (2F-PheBz4;
also designated ortho-monofluoro-Phe324) at position 324 markedly stabilizes the isolated
insulin monomer. This is ed by substitution of an aromatic amino-acid side chain by a
n—modified aromatic analogue, similar in size and shape to Phenylalanine, where the
analogue then maintains at least a portion of biological activity of the corresponding insulin or
insulin analogue ning the native aromatic side chain. Further, the modified side chain
reduces the cross-binding of insulin to the Type-I IGF receptor R) and modulates binding
to the n or such that the aberrant mitogenic properties conferred by the stabilizing
substitution HisBlOfi Asp are circumvented. It is another aspect of the present invention that the
2-F-Phe}324 modification is combined with an acidic side chain at position B10 (Asp or Glu) such
that the resulting analogue has an affinity for IGF-IR similar to that of wild-type human insulin.
It is r aspect of the present invention that such an n analogue may be formulated in at
pH 7—8 at strengths from U—lOO to U—500 (approximately 0.6 — 3.0 mM), optionally in zinc-free
formulations, with preservation of PK/PD ties similar to, or more rapid and less prolonged
than, those of regular formulations of wild-type human insulin at strength U-lOO. In one
particular embodiment, the concentration of insulin in the formulation is at least 2 mM. It is yet
another aspect of the present invention that the insulin analogue ning 2F-Phe}324 and an
acidic side chain at position B10 may contain additional substitutions in the A chain or B chain
that further enhance chemical or physical stability or that further impair self-assembly.
In l, the present invention es a pharmaceutical formulation sing
insulin having a t insulin B-chain polypeptide ning an ortho-monofluoro-
Phenylalanine substitution at position B24 in relation to the sequence of human insulin, in
combination with a substitution of an amino acid containing an acidic side chain at position B10
in relation to the sequence of human insulin selected from Aspartic Acid and Glutamic Acid,
wherein the insulin is present at a tration of between 0.6 mM and 3.0 mM. In some
particular ments the pharmaceutical formulation contains insulin at a concentration of at
least 2 mM. In one particular embodiment, the pharmaceutical formulation contains insulin at a
concentration of 2.4 mM or more.
In addition or in the alternative, the insulin analogue may be a mammalian insulin
analogue, such as an analogue of human insulin. In one set of embodiments, the B-chain
polypeptide comprises an amino-acid sequence selected from the group consisting of SEQ. ID.
NOS. 4-7 and ptides having three or fewer additional amino-acid substitutions thereof. In
still another ment, the A chain contains a substitution at position A8 (SEQ. ID, NO. 8 in
addition to B—chain cations) selected from the group consisting of SEQ. ID. NOS. 4-7.
In another embodiment, the insulin analogue may optionally contain a non-standard
amino-acid substitution at position 29 of the B chain. In one example, the andard amino
acid at B29 is norleucine (Nle). In another example, the non-standard amino acid at B29 is
omithine (Orn). In still other examples, the non—standard amino acid may be Aminobutyric acid,
ropionic acid, Diaminobutyric acid, or Diaminopropionic acid.
Also provided is a c acid encoding an insulin analogue comprising a B-chain
polypeptide that incorporates a non-standard amino acid at position B24. In one example, the
non—standard amino acid is encoded by a stop codon, such as the nucleic acid sequence TAG.
An expression vector may comprise such a nucleic acid and a host cell may contain such an
expression vector.
The invention also provides a method of lowering the blood sugar level ofa patient.
The method comprises administering a physiologically effective amount of an insulin analogue
or a physiologically acceptable salt thereof to the patient, wherein the insulin analogue or a
physiologically acceptable salt thereof contains a n polypeptide incorporating an orthomonofluoro-Phenylalanine
(2F-Phe) at position B24 and an Asp or Glu substitution at position
B10. In still another ment, the insulin analogue is a mammalian insulin analogue, such as
an ue of human insulin. In some embodiments, the B-chain polypeptide comprises an
amino-acid sequence selected from the group consisting of SEQ. ID. NOS. 4-7 and polypeptides
having three or fewer additional amino—acid substitutions thereof. In other embodiments, the A-
chain polypeptide comprises an amino-acid sequence selected from the group consisting of SEQ.
ID. NOS. 8 in combination with a B-chain polypeptide comprising an acid sequence
selected from the group consisting of SEQ. ID. NOS. 4-7.
It is a further aspect of the present invention to e a polypeptide comprising a
variant insulin B-chain polypeptide sequence containing an ortho-monofluoro-Phenylalanine
substitution at position B24 in on to the sequence of human insulin, in combination with a
substitution of an amino acid containing an acidic side chain at position B10 in relation to the
sequence of human insulin, and a substitution of a andard amino acid at position B29 in
relation to the ce of human insulin selected from the group ting of Omithine,
Diaminobutyric acid, Diaminopropionic acid, Norleucine, Aminobutyric acid, and
Aminopropionic acid. In some embodiments, the polypeptide may be a proinsulin analogue or
single—chain insulin ue.
BRIEF PTION OF THE SEVERAL VIEWS OF THE DRAWINGS
FIG. I a schematic representation of the sequence of human insulin indicating the
position of residue B24 in the B chain.
is a ribbon model of an insulin monomer showing aromatic e of PheB24
in relation to the three disulfide bridges. The ing side chains of LeuBIS (arrow) and Phe1324
are shown. The A- and B chains are otherwise shown in light and dark gray, respectively, and
the sulfur atoms of cysteines as circles.
is a space—filling model of insulin showing the Phe side chain within a
pocket at the edge of the hydrophobic core.
is a series of ball and stick (top) and space-filling (bottom) representations of
phenylalanine (Phe).
is a series of ball and stick (top) and space-filling (bottom) representations of
2F-Phe.
is a graph showing the results of or-binding studies of insulin analogues.
Relative activities for the B isoform of the insulin receptor (IR—B) are determined by competitive
binding assay in which receptor-bound 125I-labeled human insulin is displaced by increasing
concentrations of human insulin (0) or its analogues: DKP—insulin (A) and 2F—PheB24—DKP—
insulin (V); results of curve fitting are summarized in Tables 2 and 3.
is a histogram g extent of ligand—stimulated IGF-I or
autophosphorylation. IGF-I receptor-deficient mouse embryo fibroblast cells stably expressing
the human IGF-I receptor were serum-starved overnight and then treated with 10 nM ligand for 5
min and cell lysates prepared and analyzed for phosphorylated IGF-I receptor (IGF-IR) by
ELISA. Autophosphorelation by 2F-DKP is similar with HI.
shows the results of a breast-cancer—related MCF-7 colony formation assay for
mitogenecity. MCF-7 human breast cancer cells were analyzed for colony formation in soft agar
(reflecting tumorigenic ial) in the presence of 10 nM ligands after 1—week growth.
enic potential of 2F-Phe -DKP was comparable to wild-type human n and
untreated cells.
provides a graph of CD-detected guanidine denaturation. Chemical
denaturation of human insulin (HI, 0), insulin Lispro (KP, :1), AspBlO-KP-insulin (DKP, O) and
2F-PheB24-DKP—insulin (A) insulin analogs. a were collected at 25 0C in phosphate-buffer
saline (pH 7.4). Unfolding was monitered by CD at 222 nm. The ity of the BZ4-DKP
analogue exhibits a gain of 0.6(i0.2) and 1.6(i0.2) kcal/mol in stability (DDGU) relative to DKP-
insulin and human insulin, respectively (see Table 4).
is a histogram comparing the fibrillation lag times of insulin analogues.
Thioflavin T fluorescence monitered fibrillation lag time. Samples were gently agitated at 37 °C
and pH 7.4 in Zn-free phosphate-buffered saline. 2F-DKP-insulin was 3.7 and ld more
resistant to ation (as probed by lag times) relative to insulin Lispro and wild—type human
insulin, respectively.
provides a cal summary of the pharmacodynamics in anesthetized pigs
of 2F-PheB24-DKP-insulin at U-400 strength (in zinc-free Lilly diluent containing 5 mM
ethylenediaminetetraacetic acid (EDTA) at pH 7.4; middle bar) in relation to current n
products g (U-100 strength; top bar) and Humulin R U-SOO m bar).
provides a structural depiction of the l structure of 2F-Phe in the
context of a zinc KP-insulin hexamer. (A) Ribbon model of wild-type human insulin as a T3ng
zinc hexamer. (B) Corresponding ribbon model of 2F-Phe1324-KP-insulin in the same crystal
form. The variant T3Rf3 structure is similar to that of the parent hexamer, trating lack of
long-range structural perturbations and accommodation of the fluorine atom at a native-like
dimer interface.
illustrates the electron density surrounding 2F-Phe1324 in the crystal ure
of 2F-Phe1324 as determined at a resolution of 2.5 A. (A) 2F-Phe1324 and oring electron
824 and neighboring electron density in the Rf-state
density in the T-state protomer. (B) 2F-Phe
protomer. The orientation of the B24 ring and interactions of the fluoro moiety differ n
the two conformational states.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed an insulin analogue that enables rapid PK and PD to
be maintained at a broad range of insulin concentrations from U-lOO to U-SOO. The analogue
then ins at least a portion of biological activity of the corresponding unmodified insulin or
insulin analogue and maintains similar or enhanced thermodynamic stability and resistance to
fibril formation. We have invented an insulin analogue with PK/PD properties similar to or more
rapid than regulation formulations of wild-type human insulin at U—lOO strength (e. g., Humulin
R® U—100; Eli Lilly and Co.) such that these PK/PD properties are not significantly affected by
the concentration ofinsulin analogue in the range 0.6 mM — 3.0 mM.
The present invention pertains to a non-standard fiuorous ation at position
B24 to e the properties of concentrated n formulations with respect to rapidity
of absorption following subcutaneous injection. In one instance the insulin analogue is an
engineered dimer that contains acidic substitutions (Glu or Asp) at on B10, introduced to
prevent binding of zinc ions by native residue HisBIO and to destabilize the trimer interface of
insulin as defined in molecular structures of Zinc insulin rs. In another instance, the
analogue is an engineered monomer that ns, in addition to the acidic tutions at
position B10 described above, additional substitutions at positions B28 and/or B29, introduced to
destabilize the classical dimer interface of insulin as defined in molecular structures of zinc
insulin rs and zinc-free dimers. In yet another instance the dimeric and monomeric
ues described above may contain an additional substitution at position A8.
In either of two particular embodiments (2F-PheBz4-DKP-insulin (where DKP
represents AspBlo, Lys1328 and ProBZg), and 2F-PheBZ4-[AspB 10, OmB29]—insulin; where Om
designates ornithine) the present invention provides an insulin analogue that exhibits an affinity
for the Type I IGF or similar to or lower than that of wild-type human insulin, an activity
in stimulating the autophosphorylation of the Type I IGF receptor that is r to or lower than
that of wild-type human insulin, and an activity in stimulating the proliferation of a human
breast-cancer—derived cell line that is similar to or lower than that of wild-type human insulin.
The present invention is not limited, r, to 2F-Phe1324—derivatives of human insulin and its
analogues. It is also envisioned that these substitutions may also be made in dimeric and
monomeric analogues derived from animal insulins such as porcine, bovine, , and canine
insulins, by way of non—limiting examples.
It has been discovered that BZ4-DKP-insulin and 2F-PheB24-[AspBlo, Orn829]-
insulin, when ated in Lilly Diluent and following subcutaneous injection in a male Lewis
rat rendered diabetic by streptozotocin, will direct a reduction in blood glucose concentration
with a potency similar to that of ype human n in the same formulation. It has also
been discovered that 2F-PheBZ4-DKP-insulin and 2F-PheB24-[AspB10, -insulin, when
formulated in Lilly Diluent and following subcutaneous injection in an anesthetized Yorkshire
pig whose endogenous b-cell secretion of insulin was suppressed by enous administration
of octreotide, will direct a ion in blood glucose concentration with a potency similar to that
of wild-type human insulin in the same formulation.
In addition or in the alternative, the insulin analogue of the present invention may
contain a standard or non-standard amino—acid substitution at position 29 of the B chain, which is
lysine (Lys) in wild-type insulin. In one example, the non-standard amino acid at B29 is
norleucine (Nle). In another example, the non—standard amino acid at B29 is ornithine (Om).
Furthermore, in view of the similarity between human and animal insulins, and use in
the past of animal insulins in human patients with diabetes mellitus, it is also envisioned that
other minor modifications in the sequence of insulin may be introduced, especially those
substitutions considered “conservative.” For example, onal substitutions of amino acids
may be made within groups of amino acids with similar side chains, without departing from the
present invention. These include the neutral hydrophobic amino acids: Alanine (Ala or A),
Valine (Val or V), Leucine (Leu or L), Isoleucine (Ile or I), Proline (Pro or P), Tryptophan (Trp
or W), Phenylalanine (Phe or F) and Methionine (Met or M). Likewise, the neutral polar amino
acids may be substituted for each other within their group of Glycine (Gly or G), Serine(Ser or
S), Threonine (Thr or T), Tyrosine (Tyr or Y), Cysteine (Cys or C), ine (Glu or Q), and
Asparagine (Asn or N). Basic amino acids are ered to include Lysine (Lys or K), Arginine
(Arg or R) and Histidine (His or H). Acidic amino acids are Aspartic acid (Asp or D) and
Glutamic acid (Glu or E). Unless noted otherwise or wherever obvious from the context, the
amino acids noted herein should be considered to be o acids. Standard amino acids may
also be substituted by non-standard amino acids belong to the same chemical class. By way of
non-limiting example, the basic side chain Lys may be replaced by basic amino acids of shorter
side-chain length hine, Diaminobutyric acid, or Diaminopropionic acid). Lys may also be
replaced by the neutral aliphatic isostere Norleucine (Nle), which may in turn be substituted by
analogues containing shorter aliphatic side chains (Aminobutyric acid or Aminopropionic acid).
In one example, the insulin analogue of the present invention contains four or fewer
conservative substitutions other than the 2F-Phe and B10 substitutions of the present
invention. In a pair of particular examples, the formulation containing a variant B-chain
polypeptide ce also contains an Asn or Lys substitution at position B3 ve to human
insulin. In addition or in the alternative, the formulation may additionally include an insulin A-
chain ptide sequence containing a Glutamic acid substitution or a Histidine tution at
position A8.
As used in this specification and the claims, various amino acids in insulin or an
insulin analogue may be noted by the acid residue in question, followed by the position of
the amino acid, ally in superscript. The position ofthe amino acid in question includes the
A— or B chain of insulin where the substitution is located. Thus, Phe1324 denotes a phenylalanine
at the twenty-fourth amino acid of the B chain of insulin. Fluoro-derivatives of aromatic rings
retain planarity, but differ in bution of p electrons leading to changes in electrostatic
potential as rated in front and side views of Phenylalanine (Fig. 3A) relative to 2F—
Phenylalanine (Fig. 3B). As used herein, the d position of a particular substitution should
be understood to be the position ve to wild type human insulin, regardless of the particular
species being used in any particular embodiment under discussion. In this way, the location of a
substitution will be identifiable regardless of any insertions, extensions or deletions in a
particular ptide.
1324
modification -
The present invention envisions that 2F at Phe introduces an
electronegative atom and electrostatic dipole moment that result in (i) dynamic
stabilization of the n monomer and (ii) an alteration in the functional character of the
receptor-binding surface. Whereas there are substitutions known in the art that enhance the
stability of insulin in concern with augmentation of receptor binding, 2F-Phe1324 stabilizes n
while decreasing receptor binding. In particular, this alteration serves to counteract the effects of
acidic substitutions at position B10 (Asp or Glu) to enhance binding to, and signaling through,
the Type I IGF receptor; this alteration serves to counteract the effects of such B10 substitutions
to e binding to the insulin or, presumably by reducing the residence time of the
analogue on the receptor; and by means of these and other possible mechanisms, 2F-PheB24
enables the incorporation of acidic residues at B10 without incurring excess mitogenicity relative
to wild-type human n.
The phenylalanine at B24 is an invariant amino acid in functional insulin and contains
an aromatic side chain. The biological importance of Phe in insulin is indicated by a clinical
mutation (Ser ) causing human diabetes mellitus. While not wishing to be bound by ,
Phe1324 is believed to pack at the edge of a hydrophobic core at the classical receptor binding
surface. The models are based on a crystallographic protomer (2-Zn molecule 1; Protein
Databank identifier 4INS). Lying within the C—terminal B-strand of the B chain ues B24-
B28), Phe1324 s the central a—helix (residues B9-B19) (Fig. 2A). In the insulin r
BIS and CysBl9;
one face and edge of the aromatic ring sit within a shallow pocket defined by Leu
the other face and edge are exposed to solvent (Fig. 2B). This pocket is in part surrounded by
main-chain carbonyl and amide groups and so creates a complex and asymmetric electrostatic
environment with irregular and loose steric borders. In the insulin dimer, and within each of the
side chain of Phe packs Within. -
three dimer interfaces of the insulin r, the a more
tightly contained spatial environment as part of a cluster of eight aromatic rings per dimer
interface (TyrBlG, PheB24, l’he1325 , Tyr1326 and their dimer-related mates). Irrespective of theory,
substitution of the aromatic ring of PheB24 by a 2F derivative preserves l hydrophobic
packing within the dimer interface while ucing favorable asymmetric electrostatic
interactions within the insulin monomer.
The present invention pertains to a andard modification at position B24 to
improve the properties of ultra—concentrated formulations of dimeric or monomeric insulin
analogues with respect to physical stability, chemical stability, and mitogenicity. Because of
these improvements, the n analogues can be formulated at strengths greater than U-100 and
up to U-500 such that, irrespective of the concentration of insulin analogue, the formulation
maintains a rapidity of absorption and pharmacologic activity following subcutaneous ion
similar to that ofa regular wild-type human insulin U-100 formulation; examples ofthe latter are
Humulin® R U-100 (Eli Lilly and Co) or n® R U-100 (Novo-Nordisk). In one instance
the n analogue contains 1324 in association with an acidic substitution (Asp or Glu) at
position B10. In yet other instances the non-standard amino-acid tution at B24 is
accompanied both by an acidic substitution at B10 and by a non-standard substitution at position
B29 or by three or fewer standard substitutions elsewhere in the A- or B chains.
It is envisioned that the substitutions of the present invention may be made in any of a
number of existing insulin analogues. For example, the ortho-fluoro tive of Phenylalanine
at position B24 (2F-PheB24) provided herein may be made in insulin analogues that contain an
acidic residue at on B10 in the context of insulin Lispro ([LysB28, PrOB29]-insulin, herein
abbreviated KP-insulin), insulin Aspart (Asszg-insulin), insulin Glulisine ([LysB3, GluB29]-
insulin), or other modified insulins or insulin analogues, or within various pharmaceutical
ations, such as regular insulin, NPH insulin, lente insulin or ultralente insulin, in addition
to human insulin. Insulin Aspart contains an Asp substitution and is sold as Novalog® whereas
insulin Lispro contains Lys1328 and Pro substitutions and is known as and sold under the name
B28 and ProB 9and2 .
Humalog®; insulin Glulisine ns substitutions Lys 1s known as and sold
under the name Apidra®. These analogues are described in US Pat. Nos. 5,149,777, 5,474,978,
and 7,452,860. These analogues are each known as fast-acting insulins.
The amino-acid sequence of human ulin is provided, for ative purposes,
as SEQ ID NO: 1.
SEQ ID N041 (human proinsulin)
Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser—His-Leu-Val-Glu-Ala-Leu-Tyr—Leu-Val-Cys—
Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr—Pro-Lys-Thr-Arg—Arg—Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly—
Gln-Val-Glu-Leu-Gly—Gly—Gly-Pro—Gly—Ala—Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly—Ser-
Leu-Gln-Lys-Arg-Gly-Ile-Val-Glu—Gln-Cys-Cys-Thr-Ser—Ile-Cys-Ser-Leu-Tyr—Gln-Leu-Glu-
Asn-Tyr—Cys-Asn
The amino-acid sequence of the A chain of human insulin is provided as SEQ ID NO:
SEQ ID NO: 2 (human A chain)
Gly—Ile-Val-Glu—Gln—Cys—Cys-Thr—Ser—Ile-Cys—Ser—Leu—Tyr-Gln—Leu-Glu-Asn—Tyr—Cys—
The amino-acid sequence of the B chain of human insulin is provided as SEQ ID NO:
SEQ ID NO: 3 (human B chain)
l—Asn—Gln-His-Leu-Cys-Gly—Ser—His—Leu-Val—Glu-Ala—Leu-Tyr—Leu-Val-Cys-
Gly-Glu-Arg-Gly—Phe-Phe-Tyr—Thr—Pro-Lys-Thr
The amino—acid sequence of a B chain of human insulin may be modified with a
substitution of a ortho-monofluoro-Phenylalanine (2F-Phe) at position B24. An e of such
a ce is provided as SEQ. ID. NO 4.
SEQ ID NO: 4
Phe-Val- Xaas-Gln-His-Leu-Cys-Gly-Ser-Xaa4-Leu-Val-Glu-Ala—Leu-Tyr—Leu-Val-Cys-
Gly-Glu-Arg-Gly— he-Try-Thr-Xaa2-Xaa3-Thr
[Xaal is 2F-Phe; Xaaz is Asp, Pro, Lys, or Arg; X2133 is Lys, Pro, or Ala; Xaa4 is Asp or
Glu; and Xaas is Asn or Lys] '
Substitution of a 2F-Phe at position B24 may optionally be combined with non-
standard substitutions at position B29 as provided in SEQ. ID. NO 5.
SEQ ID NO: 5
Phe-Val-Asn-Gln-His-Leu-Cys-Gly—Ser—Xaa4-Leu-Val—Glu—Ala—Leu—Tyr—Leu-Val-Cys—
Gly-Glu—Arg—Gly— XaaI-Phe-Try-Thr- Xaaz-Xaag—Thr
[Xaa] is 2F-Phe; Xaaz is Asp, Glu, or Pro; Xaa3 is Ornithine, Diaminobutyric acid,
Diaminoproprionic acid, Norleucine, Aminobutric acid, or Aminoproprionic acid; and Xaa4 is
Asp or Glu]
r combinations of other substitutions are also within the scope of the present
ion. It is also envisioned that the substitutions and/or additions of the present invention
may also be combined with substitutions of prior known n ues. For example, the
amino-acid sequence of an analogue of the B chain of human insulin containing the Lys and
Pro substitutions of insulin Lispro, in which the 2F-Phe1324 substitution may also be
introduced, is provided as SEQ ID NO: 6.
SE ID NO: 6
Phe—Val-Asn-Gln—His—Leu-Cys—Gly-Ser— Xaaz-Leu—Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-
Gly—Glu—Arg-Gly-Xaa] -Phe—Tyr—Thr—Lys-Pro-Thr
[Xaa] is 2F-Phe, and Xaaz is Asp or Glu]
Similarly, the amino—acid sequence of an analogue of the B chain of human insulin
containing the Asp1328 substitution of insulin Aspart, in which the 2F—Phe1324 tution may also
be introduced, is provided as SEQ ID NO: 7.
SEQ ID NO: 7
Phe—Val—Asn-Gln-His-Leu—Cys—Gly-Ser—Xaag-Leu-Val—Glu—Ala—Leu-Tyr-Leu-
Val-Cys-Gly-Glu-Arg-Gly-Xaa]-Phe-Tyr-Thr-fip—Lys-Thr.
[Xaal is 2F-Phe, and Xaaz is Asp or Glu]
In still another embodiment, the B—chain insulin analogue polypeptide contains a
Lysine at position B3, Glutamic acid at position B29, and ortho-monofluoro—Phenylalanine at
position B24 as provided as SEQ ID NO: 8.
S_EQ_1D NO: 8
Phe-Val—Lfi-Gln-His-Leu—Cys-Gly—Ser- Xaag-Leu-Val—Glu—Ala—Leu—Tyr—Leu—
Val—Cys-Gly—Glu-Arg-Gly-Xaal-Phe-Tyr—Thr—Pro—§]u—Thr.
[Xaal is 2F-Phe, and Xaaz is Asp or Glu]
A 1324 substitution may also be introduced in combination with other insulin
analogue tutions such as analogues of human insulin ning a substitution at residue
A8 as described more fully in co—pending International Application No. PCT/USO7/00320 and
US. Application Ser. No. 12/160,187. For example, the 2F-Phe1324 substitution may be present
with HisA8 or GluA8 in which the variant A chain is provided in SEQ ID NO: 9,
SEQ ID NO: 9
Gly—Ile-Val- Glu-Gln-Cys—Cys-Xaa1-Ser-Ile-Cys—Ser-Leu-Tyr-Gln-Leu-Glu-Asn-
Tyr-Cys-Asn;
wherein Xaa] is His or Glu.
The insulin analogues provided in SEQ ID NO: 4-8 may be prepared by trypsin—
catalyzed semi—synthesis in which a des—octapeptide[B23-B30] fragment of AspBlO-insulin,
GluBlO—insulin, or variants thereof containing an additional substitution at position A8, is
employed as ed in SEQ ID NOS: 10 and 11 wherein the A and B chain are connected by
cystines A7-B7 and 9 and wherein the A chain contains cystine A6—A1 1.
SEQ ID NO: ID
(A chain)
Gly-Ile-Val-Glu—Gln-Cys-Cys-Xaa-Ser—Ile-Cys-Ser—Leu-Tyr-Gln-Leu-Glu-Asn-Tyr—Cys-
wherein Xaa is Thr, His, or Glu
SEQ ID NO: 11
(B chain)
Phe-Val-Asn-Gln-His-Leu-Cys-Gly—Ser—Xaa-Leu-Val—Glu-Ala—Leu-Tyr—Leu-Val-Cys-
Gly—Glu—Arg
wherein Xaa is His or Glu.
n-mediated semisynthesis also s a synthetic octapeptide containing
ortho-monofluoro-Phenylalanine (2F—Phe) as provided in SEQ ID NOS: 12-14.
SEQ ID NO: 12
Gly-Xaal-Phe-Tyr—Thr—Pro-Xaaz—Thr.
[Xaa] is 2F-Phe and X2182 is Lys containing a removable ting group attached to its
eamino function]
SEQ ID NO: 13
Gly-Xaal -Phe-Tyr-Thr—Pro-Xaag-Thr.
[Xaal is 2F-Phe and Xaaz is Glu]
SEQ ID NO: 14
Gly-Xaal-Phe—Tyr—Thr-Pro-Xaa2-Thr.
[Xaa] is 2F-Phe and Xaaz is Norleucine, Ornithine, Diaminobutyric Acid, or
Diaminopropionic Acid]
SE ID NO: 15
Gly-Xaa,-Phe-Tyr-Thr-Xaa2-Pro—Thr.
[Xaa] is 2F-Phe and X21212 is Asp or Glu]
SEQ ID NO: 16
Gly-Xaa]-Phe-Tyr—Thr-flp-Xaag-Thr.
[Xaa] is 2F-Phe and Xaaz is Lys containing a removable protecting group attached to its
e-amino function]
SEQ ID NO: 17
Gly-Xaa1-Phe-Tyr-Thr-L)§-Prg-Thr.
[Xaal is 2F-Phe]
An monofluoro-Phenylalanine substitution at B24 may also be introduced as an
additional tution into a single-chain n analogue as disclosed for example in US.
Patent No. 957.
Ortho-monofluoro-Phenylalanine (2F-Phe) was introduced within an engineered
insulin monomer of native activity, designated DKP-insulin, which contains the substitutions
Asp1310 (D), Lys1328 (K), and Pro1329 (P). These three substitutions on the surface of the B chain
are believed to impede formation of dimers and hexamers and to be incompatible with hexamer
assembly in the absence or presence of zinc ions and in the e or presence of a phenolic
preservative. ulin (which lacks the Asp substitution of DKP insulin) is the active
ingredient of g® (also designated insulin Lispro), currently in clinical use as a rapid—
acting insulin analogue formulation. The sequence of the B-chain polypeptide for this variant of
DKP-insulin is provided as SEQ ID NO: 6. Ortho-monofluore-Phenylalanine (2F-Phe) was also
introduced at position B24 within an engineered insulin monomer of ed activity,
designated DDP-insulin, which contains the substitution AspBIO (D) in addition to the DP
substitutions Asp1328 (K) and ProB29 (P) in accordance with the general scheme provided in SEQ.
ID. NO 4. 2F-Phe1324 was also introduced into non-standard human insulin analogues ning
Omithine position B29 in accordance with the general scheme provided in SEQ. ID. NO 5.
The above ues of AspBIO-insulin were prepared by trypsin-catalyzed semi-
synthesis and purified by high-performance liquid chromatography (Mirmira, R.G., and Tager,
HS, 1989. J Biol. Chem. 264: 6349-6354.) This protocol employs (i) a synthetic octapeptide
representing residues (N)—GF*FYTQT (including d residue (F*) and “KP” substitutions
(underlined); SEQ ID NO: 15) and (ii) truncated analogue des-octapeptide[B23-B30]—insulin or,
in the case of sulin analogues, AspBI0-des—octapeptide[B23—B30]-insulin (SEQ ID NO:
11). Because the octapeptide differs from the wild-type B23-B30 sequence (GF*FYTPKT; SEQ
ID NO: 12) by interchange of Pro1328 and Lys1329 (italics), protection of the lysine e-amino group
is not required during n treatment. In brief, des-octapeptide (15 mg) and octapeptide (15
mg) were dissolved in a mixture of dimethylacetamide/ 1,4-butandiol/0.2 M Tris acetate (pH 8)
containing 10 mM calcium acetate and 1 mM ethylene diamine tetra-acetic acid (EDTA)
(35:35:30, v/v, 0.4 mL). The final pH was adjusted to 7.0 with 10 mL of N—methylmorpholine.
The solution was cooled to 12 °C, and 1.5 mg of TPCK-trypsin was added and incubated for 2
days at 12 °C. An additional 1.5 mg of trypsin was added after 24 hr. The reaction was acidified
with 0.1% trifluoroacetic acid and d by preparative reverse-phase HPLC (C4). Mass
spectrometry using matrix-assisted laser desorption/ionization time—of—flight (MALDI—TOF;
d tems, Foster City, CA) in each case gave expected values (not shown). The
general protocol for solid—phase synthesis is as described (Merrifield et al., 1982. Biochemistry
21: 031). 9-fluoren—9-yl-methoxy—carbonyl (F-moc)—protected phenylalanine analogues
were sed from Chem-Impex International (Wood Dale, IL).
The above protocol was also employed to prepare an analogue of AspBIO—human
insulin in which Phe was substituted by 2-F-Phe and in which 8 was substituted by Asp
(D) and Lys1329 was substituted by Pro (P). This analogue is designated 2F-PheB24-DDP-insulin
wherein the acronym DDP refers in turn to the identity of the amino—acid residue at respective
positions B10, B28, and B29.
The above protocol was also employed to prepare an analogue of AspBIO—human
n containing Omithine (O) at position B29 and to introduce 2F-Phe1324 in this context. The
method of preparation of this analogue exploited the andard amino-acid substitution at
position 29 to eliminate the c site ordinarily t within the C-terminal octapeptide of
the B chain (i.e., between Lys1329 and ThrB30) while maintaining a Proline (P) at position 28.
ProB28 is believed to contribute to the stability of the dimer interface within the insulin hexamer,
and so this method of preparation provides near-isosteric models of wild-type insulin in which
other ations may conveniently be incorporated without the need for cumbersome side—
chain protection. This analogue is designated 2F-Phe1324—DPO-insulin wherein the m DPO
refers, as above, to the identity of the amino-acid residue at respective ons B10, B28, and
B29. The B24—modified insulin analogues were ted to some or all of the following
assays. Biological potency was assessed in a diabetic rat model and by euglycemic clamp in
anesthetized Yorkshire pigs; receptor-binding activity values shown are based on ratio of
hormone-receptor dissociation constants relative to human n (the activity of human insulin
is thus 1.0 by definition with standard errors in the activity values otherwise less in general than
%); assays of hormone-stimulated autophosphorylation of the Type I IGF receptor were
performed in a mouse embryo fibroblast expressing the human IGF-IR y provided by Drs.
Deepali Sachdev and Douglas Yee of the University of Minnesota); assays of mitogenicity in a
human cell line employed breast-cancer-derived cell line MCF-7 as described (Milazzo G,
Sciacca L, Papa V, Goldfine ID, i R. (1997) AspBlO-insulin induction of increased
mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for
ed interactions with the insulin-like growth factor-I receptor. M01. og. 18, 19-25);
thermodynamic stability values (free energies of unfolding; DGU) were assessed at 25° C based
on a two—state model as extrapolated to zero denaturant concentration; resistance to fibril
ion was evaluated by measurement of lag times (in days) required for initiation of protein
fibrillation on gentle agitation at 300 C in zinc-free phosphate—buffered saline (pH 7.4) as
described (Yang, Y., Petkova, A.T., Huang, K., Xu, B., Hua, Q.X., Y, I.J., Chu, Y.C., Hu, S.Q.,
Phillips, N.B., Whittaker, J., lsmail-Beigi, F., , R.B., Katsoyannis, P.G., Tycko, R., &
Weiss, MA. (2010) An Achilles” Heel in an amyloidogenic protein and its repair. Insulin
fibrillation and therapeutic design. J. Biol. Chem. 285, 10806—10821). Results of curve fitting
are ized in Table 4 and rated in Figure 8.
Circular ism (CD) spectra were obtained at 4° C and/or 25° C using an Aviv
spectropolarimeter (Weiss et al., Biochemistry 39: 15429—15440). Samples contained ca. 25 mM
DKP-insulin or analogues in 50 mM potassium phosphate (pH 7.4); samples were diluted to 5
mM for guanidine-induced denaturation studies at 25° C. To extract free energies of unfolding,
denaturation tions were fitted by non-linear least squares to a two-state model as described
by Sosnick et al., Methods Enzymol. 317: 393-409. In brief, CD data q(x), where x indicates
the concentration of denaturant, were fitted by a nonlinear least-squares program according to
(7 007,20 »m.i-)/Ii'r
+ q”e
q<x) = 3‘4 .
1 + e7(D(1”10—m.\‘)/RI
where x is the concentration of ine and where (9/; and 63 are baseline values in
the native and unfolded states. Baselines were imated by pre— and post—transition lines
gA(x) =q/ilzo +mAx and gB(x) : quo +me_ The m values ed in fitting the variant
unfolding transitions are lower than the m value obtained in fitting the wild—type unfolding curve.
To test whether this difference and apparent change in AGu result from an inability to measure
the CD signal from the fully unfolded state, simulations were performed in which the data were
extrapolated to plateau CD values at higher concentrations of guanidine; essentially identical
estimates of AGu and m were obtained. Representative data are shown in Figure 7. The far-
ultraviolet circular dichroism (CD) spectrum of the 2F-Phe -DKP-insulin ue is similar to
those of the parent analogue DKP—insulin.
The baseline thermodynamic stability of ulin, as inferred from a ate
model of denaturation at 25 °C, is 3.0 i 0.1 kcal/mole. CD—detected guanidine ration
studies indicate that the 2F-Phe substitution is associated with a gain in thermodynamic
stability in the context of KP-insulin (DDGu 1.1 :l: 0.2 kcal/mole) and in the context of DKP-
insulin (DDGu 0.60 i 0.2 kcal/mole). r, the physical stability ofthe B24-DKP-insulin
was found to be markedly greater than that of KP-insulin as evaluated in triplicate during
incubation; the ns were made 300 uM in phosphate—buffered saline (PBS) at pH 7.4 at 30°
C under gentle ion. The samples were observed for 20 days or until signs of precipitation
or frosting ofthe glass vial were observed. Results are shown in Figure 8 (see also Table 4).
Relative receptor—binding activity is defined as the ratio of the hormone-receptor
iation constants of analogue to wild-type human insulin, as measured by a competitive
dlsplacement_ . I-human insulin., , Microtiter. . . plates (Nunc Max1sorb) were. assay us1ng strip
incubated overnight at 4° C with AU5 IgG (100 ul/well of 40 mg/ml in phosphate-buffered
saline). Binding data were analyzed by a two—site sequential model. Data were corrected for
nonspecific binding (amount of radioactivity remaining membrane associated in the presence of
1 mM human insulin. In all assays the percentage of tracer bound in the absence of ing
ligand was less than 15% to avoid ligand-depletion artifacts. Representative data are provided in
Figure 4.
To assess hypoglycemic potencies of DKP—insulin analogues, DDP-insulin analogues,
and DPO insulin analogues or there 2F-Phe1324 derivatives relative to ulin or wild—type
human insulin in vivo, male Lewis rats (mean body mass ~300 grams) were rendered diabetic by
treatment with streptozotocin. (This model proVides a probe of potency but not degree of
acceleration of pharmacokinetics as (i) wild-type insulin, ulin, and 8-insulin exhibit
similar patterns of effects of blood glucose concentration and (ii) these patterns are unaffected by
the ce of absence of zinc ions in the formulation at a stoichiometry sufficient to ensure
assembly of insulin hexamers.) Protein ons containing wild-type human insulin, insulin
analogues, or buffer alone (protein—free e diluent obtained from Eli Lilly and Co.; composed
of 16 mg glycerin, 1.6 mg meta-cresol, 0.65 mg phenol, and 3.8 mg sodium ate at pH
7.4.) were injected subcutaneously, and resulting changes in blood glucose were monitored by
serial measurements using a al glucometer (Hypoguard Advance Micro—Draw . To
ensure uniformity of formulation, insulin analogues were each re—purified by reverse-phase high—
performance liquid chromatography (rp-HPLC), dried to powder, dissolved in diluent at the same
maximum protein concentration (300 mg/mL) and re-quantitative by analytical C4 rp—HPLC;
dilutions were made using the above buffer. Rats were injected aneously at time t = 0 with
mg insulin in 100 u] of buffer per 300 g rat. This dose corresponds to ca. 67 mg/kg body
weight, which corresponds in international units (IU) to 2 lU/kg body weight. esponse
studies of KP-insulin indicated that at this dose a near-maximal rate of glucose disposal during
the first hour following injection was achieved. Five rats were studied in the group receiving 2F—
PheB24-DKP-insulin, 2F-PheB24-DDP—insulin, or 2F-PheBZ4-DPO, and five ent rats were
studied in the l group receiving KP-insulin or wild-type human insulin; these rats were
randomly selected from a colony of 30 diabetic rats. The two groups exhibited similar mean
blood glucose concentrations at the start of the experiment. Blood was obtained from clipped tip
of the tail at time 0 and every 10 minutes up to 90 min; in some studies the time period was
ed to 180 min or 240 min. The efficacy of insulin action to reduce blood glucose
concentration was calculated using the change in concentration over time (using mean
squares and initial region of linear fall) divided by the concentration of insulin injected. These
data thus suggest that the biological potency of 2F-Phe1324-DKP-insulin is equivalent to that of
KP—insulin in a zinc hexamer formulation; the other 2F-Phe1324 insulin analogues were not tested
in the rat model.
To assess PK, PD, and potency of insulin analogues in an animal model predictive of
BIO . . . .
pharmacologic properties in humans, 2F—Phe1324 derivatives of Asp -conta1n1ng human insulin
analogues were investigated in adolescent Yorkshire farm pigs (weight 35-45 kg). On the day of
study, each animal ent anesthesia induction with Telazol and general anesthesia with
isoflurane. Each animal was endotreacheally intubated with continuous ring of oxygen
saturation and dal expired C02. Although the animals were not diabetic, islet function was
suppressed in the OR by subcutaneous ion of octreotide acetate (44 mg/kg) approximately
min before beginning the clamp study and every 2 h thereafter. After IV catheters were
placed and baseline euglycemia established with 10% dextrose infusion, an subcutaneous
injection of the insulin was given through the catheter. In order to quantify peripheral insulin-
mediated glucose uptake, a variable-rate e infusion was given to maintain a blood glucose
concentration of approximately 85 mg/dl. This glucose infusion typically will be required for 5-
6 hours, i.e., until in control studies of Humulin® glucose infusion rates were typically observed
to return to pre-insulin baseline values. Glucose trations were measured with a Hemocue
201 portable glucose analyzer every 10 min (with standard error 1.9%).
The computerized protocol for glucose clamping was as described (Matthews, D. R.,
and Hosker, J. P. (1989) Diabetes Care 12, 156-159). In brief, 2—ml blood samples for insulin
assay were obtained ing to the following schedule: from 0 — 40 min after insulin delivery:
-minute intervals; from 50 — 140 min: 10-minute intervals, and from 160 min — to the point
when GIR is back to baseline: 20—min intervals. For PK/PD a 20-min moving mean curve fit
and filter is applied. PD was measured as time to half—maximal effect (early), time to half-
maximal effect (late), time to maximal effect, and area-under—the—curve (AUC) over baseline.
For each of these es, the fitted curve, not the raw data, were employed in subsequent
analyses. Each of three pigs underwent two studies: one with Chlorolog and one at the same
dosage (0.5 max dose) with U—500 ator n® R U—500 (Eli Lilly and Co.,
Indianapolis, IN) and U-lOO comparators Humalog® and l Humulin® (Lilly Laboratories,
Indianapolis, IN). The s indicate that 2F-PheB24-DKP-insulin and 2F—PheB24—DDP-insulin
retain rapid-acting PD when concentrated to U-400 strength (2.4 mM; 2F-PheB24-DKP-insulin)
or U-500 strength (3.0 mM; 2F-PheB24-DDP-insulin). PD parameters are summarized in Table 1
and in graphical form in Figure 9.
Table 1.
PD Studies of 2F-Phe1324 Analogues in Anesthetized Yorkshire Pigsa
Protein Strength Additive 11/2 2me } Tfix 11/2 [TM (late)
A. Control Studies 0fHumulin® R U—500 (pigs 1-4)b
wild-type U-500 none 122 min 240 min 357 min
wild—type U-500 none 77 min 180 min 342 min
wild-type U—500 none 100 min 180 min 342 min
wild-type U-500 none 95 min 200 min 217 min
B. Studies 0f2F-PheB24-DKP—insulin (pig 5)6
KP-insulin U-100 noned 61 min 120 min 193 min
2F-DKP-ins U—100 none 62 min 130 min 186 min
KP-insulin U-400 EDTAe 105 min 190 min 274 min
2F-DKP—ins U-400 EDTAf 28 min 140 min 228 min
C. Studies 0f2F-PheB24-DDP-insulin (pig 6%
KP-insulin U-100 noned 36 min 100 min 160 min
2F-DDP-ins U-100 EDTAh 33 min 100 min 172 min
D. Studies of2F—PheB24-DDP—insulin (pig 7)g
wild—type U-500b none 95 min 200 min 271 min
2F—DDP-ins U-500 EGTAl 76 min 180 min 280 min
aPD, pharmacodynamics. Key results are shown in bold. bFour different pigs were used in
control studies of Lilly U-500 as formulated by the manufacturer (part A). 'l'hese animals differed
in turn from used in the studies of 2F-l’heH24 analogs: the various pigs were eless r in
age and body mass. CThe three trials of 2F-l’heBz4—DKP-insulin (abbreviated 2F-DKP-ins) were
ted in a single pig. llKP-insulin was used as formulated by the manufacturer (Humalog®;
Eli Lilly and C0.). eEDTA was added to a concentration of 5 mM to the formulation buffer used
in the Lilly U-100 Humalog® product. 2‘This ue is abbreviated as 2F—DDP-ins. hEDTA was
added to a concentration of 5 mM to a zinc-free formulation in which phosphate buffer was
replaced by THAM buffer (2—aminohydroxymethyl-propane-1,3-diol); the formulation was
otherwise similar to Lilly Diluent.
Because the AspBlO tution in the context of unmodified human insulin (AspBlo-
n) was observed to exhibit enhanced mitogenicity ve to wild—type insulin in associated
with excess mammary tumor formation in Sprague-Dawley rats (Oleksiewicz, M.B., Bonnesen,
C., Hegelund, A.C., Lundby, A., Holm, G.M., Jensen, M.B., & Krabbe, J.S. (2011) Comparison
of intracellular signalling by insulin and the hypermitogenic AspB10 analogue in MCF-7 breast
adenocarcinoma cells. 1 Appl. Toxicol. 31, 329-41 and references therein), we undertook
mammalian cell-based s of hormone—stimulated autophosphorylation of the Type I IGF
receptor (IGF-IR) in a mouse embryo fibroblast cell lacking endogenous IGF receptors and
stably transfected to s human IGF-IR; results are illustrated in Figure 5. The cells were
grown to 75% confluence, starved of serum ght and then treated with 10 nM hormone
(wild-type insulin, IGF—I, AspBlO-insulin, AspBIO-OmBzg-insulin, DKP—insulin, 2F—PheBz4-DKP-
insulin, or 2F-Phe1324—DPO-insulin). Cell lysates were in each case prepared and analyzed for
phosphorylated IGF-I receptor by anti-phospho—IGF-IR ELISA as described by the vendor (Cell
Signaling Technologies, Inc.). Studies were performed in triplicate. The s demonstrate
that whereas AspBlO-insulin exhibits more profound autophosphorylation ve to human
insulin, the 1324 modification restores the level of autophosphorylation to that
indistinguishable from that of ype human insulin. Further, the set of hormones and
analogues was tested for their ability to stimulate the proliferation of human breast-cancer cell
line MCF-7 as described (Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R. (1997) AspBlO-
insulin induction of increased mitogenic responses and phenotypic changes in human breast
epithelial cells: ce for enhanced ctions with the insulin—like growth factor-I receptor.
M01. Carcinog. 18, 19-25). The cancer cells were analyzed for colony formation in soft agar
(reflecting tumorigenic potential) in the presence of 10 nM ligands after 1 week of ;
results are illustrated in Figure 6. Whereas AspBlO-insulin stimulates more growth than does
wild—type human insulin, the r addition of the 2F-Phe1324 modification reduces mitogenicity
to a level inguishable from that of wild-type human insulin.
Structural accommodation ofthe 2F—Phe modification was analyzed in a
monomeric context h 2D-NMR s of 2F-PheBz4—DKP-insulin. A native-like pattern
of lH-NMR chemical shifts and nuclear Overhauser effects (NOES) was observed; molecular
models based on distance-geometry and simulated annealing were similar to those obtained in
2D-NMR s of DKP-insulin. Additional structural studies were undertaken by single-
crystal X-ray crystallography. Crystals based on zinc KP-insulin hexamers were grown as
described (Liu, M., Wan, Z., Chu, Y.C., Aladdin, H., Klaproth, B., Choguette, M., Hua, Q.X.,
Mackin, R., Rao, J.S., De Meyts, P., Katsoyannis, P.G., Arvan, P. & Weiss, M.A. (2009) The
crystal ure of a “nonfoldable” insulin: impaired folding efficiency despite native ty. J.
Biol. Chem. 284, 35259-35272). In brief, crystals were grown by hanging-drop vapor diffusion in
the presence of a 1:25 ratio of Zn2+ to protein monomer and a 3.721 ratio of phenol to protein
monomer in Cl . Drops consisted of 1 ul of protein solution (10 mg/ml in 0.02 M
HCl) mixed with 1 ul of oir on (0.02 M Tris—HCl, 0.05 M sodium citrate, 5%
acetone, 0.03% phenol, and 0.01% zinc acetate at pH 8.1). Each drop was ded over 1 ml
of reservoir solution. Crystals (space group R3) were obtained at room temperature after two
weeks. Data were collected from single crystals mounted in a rayon loop and flash frozen to 100
K. Reflections from 24.98-2.50 A were measured on CCD detector system on synchrotron
radiation at Advanced Photon Source (APS) at Argonne National Laboratory, Chicago. Data
were sed with programs HKL2000 (Z. Otwinowski and W. Minor (1997) Processing of X-
ray Diffraction Data Collected in Oscillation Mode ", Methods in Enzymology, Volume 276:
Macromolecular Crystallography [C.W. Carter, Jr. & R. M. Sweet, Eds], Academic Press (New
York), part A, pp. 307-26.). The l exhibited unit-cell parameters: a=b=77.98 A, c=37.14
A, a=B=90°, y=120°. The structure was determined by molecular replacement using CNS.
Accordingly, a model was obtained using the native TR dimer (Protein Databank (PDB)
identifier lLPH following removal of all water molecules, zinc and chloride ions). A translation-
function search was performed using coordinates from the best solution for the rotation function
following analysis of data between 15.0 and 4.0 A resolutions. Rigid—body refinement using
CNS, employing overall anisotropic temperature factors and bulk-solvent tion, yielded
values of 0.29 and 0.33 for R and Rfi-ee, respectively, for data between 25.0 and 3.0A resolution.
Between refinement cycles, 2F,,—FC and FO-FL. maps were calculated using data to 2.50 A
tion; zinc and de ions and phenol les were built into the structure using the
program 0. The geometry was continually monitored with PROCHECK; zinc ions and water
molecules were built into the ence map as the refinement proceeded. Calculation of omit
chain N terminus of each monomer) and further
maps ially in the first eight residues of B
refinement were carried out using CNS, which implement maximum-likelihood n-angle
dynamics and conjugate-gradient refinement.
The structures are similar to those of the parent analog as illustrated in Figure 10.
s the location of the aromatic ring is similar to that of the unmodified residue in wild—type
n, the T and Rf—state protomers exhibit distinct mations as illustrated by the electron-
density maps shown in Figure 11. In each case the orientation of the 2F-Phe aromatic ring
with respect to an individual insulin protomer leaves a native-like outer dimerization interface.
Irrespective of theory, a T-like orientation was also observed in 2D-NMR s of the
monomeric 2F-PheB24-DKP-insu1in analogue and is likely to accrue ble electrostatic
interactions, thereby rationalizing the increased thermodynamic stabilities of 2F-Phe insulin
analogues. In this conformation the electronegative fluoro-substituent is near the partial ve
325 B26
s of two amide nitrogens (the main-chain peptide NH moieties of Phe and Tyr ).
To test the compatibility of the 2F-Phe modification with dimerization (as
pertinent to 2F-PheB24-DPO-insulin and related analogues in which residues B28 and B29 do not
B24 modification
impair dimerization), the 2F-Phe was introduced into framework otherwise
capable of hexamer formation to enable spectroscopic analysis of cobalt-mediated (COB)
hexamer assembly and the kinetic analysis of hexamer disassembly. The kinetic ity of
insulin analogue hexamers was assessed at 25° C relative to that of the wild—type human insulin
hexamer as a Co2+ complex in the presence of 2.2 cobalt ions per hexamer and 50 mM phenol in
a buffer consisting of 10 Tris-HCl (pH 7.4). The assay, a modification of the procedure of Beals
et al. aum, D.T., Kilcomons, M.A., DeFelippis, M.R., & Beals, J.M. Assembly and
B28 B29 - - -
dissociation of human insulin and Lys Pro -1nsu11n hexamers: a comparison study. Pharm
Res. 14, 25-36 (1997)), employs l absorbance at 500-700 nm to monitor the R6-hexamer-
c d—d transitions characteristic of tetrahedral cobalt ion coordination. Although the
solution at equilibrium contains a predominance of cobalt insulin hexamers or cobalt insulin
analogue hexamers, this equilibrium is characterized by opposing rates of insulin ly and
disassembly. To initiate the assay, the solution is made 2 mM in ethylene-diamine—tetra—acetic
acid (EDTA) to sequester free cobalt ions. The time course of decay of the R6—specific
absorption band on addition of EDTA provides an estimate of the rate of hexamer disassembly.
s wild-type insulin exhibited a time constant of 419 d: 51 seconds, KP-insulin exhibited a
time constant of 114 i 13 seconds in accordance with its accelerated pharmacokinatics.
Strikingly, the ne absorption spectrum of 2F-Phe -DPO-insulin is similar to that of wild-
type human insulin, ting that the 2F-Phe modification does not prevent formation of a
native-like dimer interface.
Structural odation of the 2F-PheB24 modification was analyzed in a
monomeric context through 2D-NMR studies of 2F-PheBZ4-DKP-insulin. A native-like pattern
of IH-NMR chemical shifts and nuclear Overhauser effects (NOEs) was observed; molecular
models based on distance-geometry and simulated annealing were similar to those obtained in
2D-NMR studies of DKP-insulin. Additional ural studies were undertaken by single-
crystal X-ray crystallography. Crystals based on zinc ulin hexamers were grown as
described (Liu, M., Wan, Z., Chu, Y.C., Aladdin, H., Klaproth, B., Choguette, M., Hua, Q.X.,
Mackin, R., Rao, J.S., De Meyts, P., Katsoyannis, P.G., Arvan, P. & Weiss, M.A. (2009) The
crystal structure of a “nonfoldable” insulin: impaired folding efficiency despite native ty. J.
Biol. Chem. 284, 35259-35272). The structures are similar to those of the parent analogue as
illustrated in Figure 10. In particular, the inward orientation of the 2F-Phe aromatic ring with
respect to an individual insulin protomer leaves a native-like outer dimerization interface.
Irrespective of theory, this inward orientation was also ed in 2D-NMR studies of the
monomeric 2F-Phe1324—DKP-insulin analogue and is likely to accrue favorable electrostatic
ctions, thereby rationalizing the increased thermodynamic ities of 2F-Phe1324 insulin
analogues.
Dissociation constants (Kd) were determined as described by Whittaker and Whittaker
(2005. J Biol. Chem. 280: 20932—20936), by a competitive displacement assay using 125I—TyrAM—
insulin (kindly provided by Novo—Nordisk) and the purified and solubilized insulin receptor
(isoforrn B or A) in a microtiter plate antibody capture assay with minor modification;
transfected receptors were tagged at their C-terminus by a triple repeat of the FLAG epitope
(DYKDDDDK) and microtiter plates were coated by anti-FLAG M2 onal antibody
(Sigma). The percentage of tracer bound in the e of ing ligand was less than 15%
to avoid ligand—depletion artifacts. g data (illustrated in Fig. 5) were analyzed by non-
linear sion using a heterologous competition model (Wang, 1995, FEBS Lett. 360: 111-
l 14) to obtain dissociation constants. Results are ed in Table 2 (2F—Phe1324 KP—insulin
analogue ve to KP-insulin) and Table 3 (templates DKP, DDP, and DPO; see footnote to
Table 3); dissociation constants are provided in units of nanomolar. (The two studies were
conducted on different dates with different preparations of insulin receptor (IR isoform B; IR-B)
and IGF receptor (IGF-IR) and so are tabulated independently.) The 2F-Phe1324 modification of
KP-insulin reduces IR-B receptor-binding affinities by between twofold and threefold; such
small reductions are typically associated with native or near-native ycemic potencies in
vivo as demonstrated herein in diabetic Lewis rats. No significant increase was observed in the
cross-binding of B24-KP-insulin to IGF-IR. The 2F-PheB24 modification of DKP-insulin
s IR-B receptor-binding affinities by less than d; a trend toward increased cross-
binding to IGF—IR was observed near the limit of tical significance.
Table 2
Binding of Insulin Analogues to Insulin Receptor and IGF Receptor
Protein IR—B binding IGF-1R binding
insulin 0.063 a: 0.014 nM 5.6 i 0.9 nM
KP-insulin 0.062 d: 0.011 nM 8.2 d: 1.2 nM
2F-PheBz4-KP-insulin 0.472 a: 0.011 nM 34.1 i 1.2 nM
IR-B, B isoform of the insulin receptor; , Type 1 IGF receptor
Table 3
Binding of Insulin Analogues to Insulin Receptor and IGF Receptor
Protein lR-B binding IGF-1R binding
A. DKP Template
Insulin* 0.063 i 0.014 nM 5.6 :l: 0.9 nM
sulin 0.020 1 0.003 nM 1.8 i 0.3 nM
2F-PheB24—DKP-insulin 0.131 i 0.020 nM 9.2 :1: 1.2 nM
B. DDP Template
insulin 0.059 i 0.010 nM 3.7 i 0.6 nM
KP-insulin 0.064 i 0.009 nM 6.2 i 1.2 nM
2F—PheBz4-DDP-insulin 0.063 a: 0.010 nM 4.8 i 0.8 nM
C. DPO Template
insulin 0.048 :I: 0.008 nM 3.1 :I: 0.5 nM
AspBIO-OmBzg—insulin 0.020 a: 0.014 nM 1.2 :I: 0.2 nM
2F—PheBz4-DPO-insulin 0.082 i 0.012 nM 4.0 i 0.6 nM
IR-B, B isoform of the insulin receptor. *, Value ed from Table 2.
The binding affinities of analogues containing the non-standard amino acid Omithine
at position B29 were similarly tested, both with and without a 2F—Phe substitution at B24.
Results are provided in Table 3 as dissociation nts relative to the human insulin receptor
isofonn B (th—B), and human IGF receptor (hIGFR). While Om1329 has similar binding
affinities for each receptor as wild type insulin, NleB29 has a sed affinity for hIR-B and
lGFR relative to wild type insulin. An analogue containing Om1329 in combination with 2F—
PheB24, however, had decreased binding affinity for both isoforms of insulin receptor and slightly
increased affinity for hIGFR. The 2F-PheB24, Nle1329 analogue had r binding affinity for
hIGFR as the Nle1329 only analogue, but had decreased binding affinity for hIR-B.
Table 4
Thermodynamic Stabilities of Insulin Analogues
n AGLl (kcal/mole) protein AG“ (kcal/mole)
insulin 3.6 i 0.1 2F-insulinb ND
ulin 2.8 i 0.1 2F-KP-insulin 3.6 i 0.1
DKP-insulin 4.3 i 0.1 2F-DKP-insulin 4.9 :I: 0.1
DDP—insulin NDa 2F-DDP-insulin 4.7 i 0.1
OmBzg-insulin ND£1 2F-OrnBZ9-insulin 4.0 i 0.1
DPO—insulin NDa 2F-DPO-insulin 5.0 i 0.1
21Free energies of unfolding (DGu) were inferred from CD-detected ine ration studies based
on application of a ate model. ND, not determined. b2F designates the ation 2F—Phe1324 in
1324
insulin (also designated ortho—monofluoro-Phe ). Analogue abbreviations: DDP, substitutions
[AspB'0, AspBZS, ProBZg]; DKP, substitutions [AspB]0, LysBzS, ProBzg]; DPO, substitutions [AspB'0,
Ornmg] with Pro at position B28 as in wild-type insulin; KP, substitutions S, ProBzg]; and Orn,
ornithine.
A method for treating a patient comprises administering an n analogue
824 modification
containing a 2F-Phe or additional acid substitutions in the A or B chain as
known in the art or described herein. In one example, the 2F-Phe1324 tuted insulin analogue
is an insulin analogue containing 2F-Phe at position B24 in the context of DKP—insulin. In
another example, 2F-Phe is substituted within AspBlO-human insulin ues containing
non—standard modifications at position B29 (Omithine or Norleucine). It is yet another aspect of
the present invention that use of non-standard amino-acid substitutions enables a rapid and
efficient method of preparation of insulin analogues by trypsin-mediated semi—synthesis using
unprotected octapeptides.
In still another example, the insulin analogue is administered by an external or
implantable insulin pump. An insulin analogue of the present invention may also contain other
modifications, such as a tether between the inus of the B chain and the N-terminus of the
A chain as described more fully in US. Patent No. 8,192,957.
A pharamaceutical composition may comprise such insulin analogues and which may
optionally include zinc. Zinc ions may be included in such a ition at a level of a molar
ratio of between 2.2 and 3.0 per hexamer of the insulin analogue. In such a formulation, the
concentration of the insulin analogue would typically be between about 0.1 and about 3 mM;
trations up to 3 mM may be used in the oir of an insulin pump. Modifications of
meal-time insulin analogues may be formulated as described for (a) “regular” formulations of
Humulin® (Eli Lilly and C0,), g® (Eli Lilly and Co.), Novalin® (Novo-Nordisk), and
Novalog® Nordisk) and other rapid—acting insulin formulations currently approved for
human use, (b) “NPH” formulations of the above and other insulin analogues, and (0) mixtures
of such formulations.
Excipients may include glycerol, e, arginine, Tris, other buffers and salts, and
anti—microbial preservatives such as phenol and meta-cresol; the latter preservatives are known to
enhance the stability of the insulin hexamer. Such a ceutical composition may be used to
treat a patient having diabetes mellitus or other medical condition by administering a
physiologically effective amount of the composition to the patient. The insulin analogues of the
present invention may be formulated in the absence of zinc ions and in the presence of 5-10 mM
ethylenediaminetetraacetic acid (EDTA) or ethyleneglycoltetraacetic acid (EGTA). The latter
ing agents are used in the absence of citrate ions.
A nucleic acid comprising a sequence that encodes a polypeptide encoding an insulin
analogue containing a sequence encoding at least a B chain of insulin with an ortho-monofluoro-
Phenylalanine at position B24 is also envisioned. This can be accomplished through the
introduction of a stop codon (such as the amber codon, TAG) at position B24 in conjunction with
a suppressor tRNA (an amber suppressor when an amber codon is used) and a corresponding
tRNA synthetase, which incorporates a non—standard amino acid into a polypeptide in response
to the stop codon, as previously described r, 1998, n Sci. 7:419-426; Xie et al., 2005,
Methods. 36: 227-23 8). The particular sequence may depend on the preferred codon usage of a
species in which the nucleic-acid sequence will be uced. The nucleic acid may also encode
other modifications of wild-type insulin. The nucleic-acid sequence may encode a modified A-
or B—chain sequence containing an unrelated substitution or extension ere in the
polypeptide or modified proinsulin ues. The nucleic acid may also be a portion of an
expression vector, and that vector may be inserted into a host cell such as a prokaryotic host cell
like an E. coli cell line, or a eukaryotic cell line such as S. cereviciae or Pischia pastoris strain or
cell line.
For example, it is oned that synthetic genes may be synthesized to direct the
expression of a B-chain polypeptide in yeast Piscia is and other microorganisms. The
nucleotide sequence of a B-chain polypeptide utilizing a stop codon at position B24 for the
e of incorporating an ortho—monofluoro-Phenylalanine at that on may be either of the
following or variants thereof:
(a) with Human Codon Preferences:
TTTGTGAACCAACACCTGTGCGGCTCACACCTGGTGGAAGCTCTCTACCTAGTGTGC
GGGGAACGAGGCTAGTTCTACACACCCAAGACC (SEQ ID NO: 18)
(b) with Pichia Codon ences:
TTTGTTAACCAACATTTGTGTGGTTCTCATTTGGTTGAAGCTTTGTACTTGGTTTGTG
GTGAAAGAGGTTAGTTTTACACTCCAAAGACT (SEQ ID NO: 19)
Similarly, a full-length pro-insulin cDNA having human codon preferences and
utilizing a stop codon at position B24 for the purpose of incorporating ortho-monofluoro-
Phenylalanine at that position may have the sequence of SEQ ID NO: 20.
TTTGTGAACC AACACCTGTG CGGCTCACAC CTGGTGGAAG CTCTCTACCT
AGTGTGCGGG GAACGAGGCT AGTTCTACAC ACCCAAGACC CGCCGGGAGG
CAGAGGACCT GCAGGTGGGG CAGGTGGAGC GCGG CCCTGGTGCA
GGCAGCCTGC AGCCCTTGGC CCTGGAGGGG TCCCTGCAGA AGCGTGGCAT
TGTGGAACAA TGCTGTACCA GCATCTGCTC CCTCTACCAG CTGGAGAACT
ACTGCAACTA G (SEQ ID NO: 20)
Likewise, a full-length human sulin cDNA utilizing a stop codon at position
B24 for the purpose of incorporating an ortho-monofluoro-Phenylalanine at that position and
having codons preferred by P. pastoris may have the ce of SEQ ID NO: 21.
TTTGTTAACC AACATTTGTG TGGTTCTCAT TTGGTTGAAG CTTTGTACTT
GGTTTGTGGT GAAAGAGGTT AGTTTTACAC TCCAAAGACT AGAAGAGAAG
ATTT GCAAGTTGGT CAAGTTGAAT TGGGTGGTGG TCCAGGTGCT
GGTTCTTTGC AACCATTGGC AGGT TCTTTGCAAA AGAGAGGTAT
TGTTGAACAA TGTTGTACTT CTATTTGTTC TTTGTACCAA TTGGAAAACT
ACTGTAACTA A (SEQ ID NO: 21)
Other variants of these ces, encoding the same polypeptide sequence, are
possible, given the synonyms in the genetic code.
Based upon the foregoing disclosure, it should now be apparent that insulin ues
provided will carry out the objects set forth above. Namely, these insulin analogues, when
ated under a broad range of protein concentrations from 0.6—3.0 mM (typically
ponding to strengths U-100 to U—500 in the cases of wild—type insulin and prandial insulin
analogues), will exhibit enhanced rates of tion from a subcutaneous depot and
pharmacologic action in the regulation of blood glucose concentration while maintaining at least
a fraction of the biological activity of wild-type insulin. Further, formulations whose rapid-
acting pharmacokinetic and pharmacodynamic ties are maintained at concentrations of
insulin analogue as high as 3.0 mM (U-500 strength) will provide enhanced utility in the safe and
effective treatment of diabetes us in the face of marked insulin resistance. It is, therefore,
to be understood that any variations evident fall within the scope of the d invention and
thus, the selection of specific component elements can be determined without departing from the
spirit of the invention herein disclosed and described.
The following literature is cited to demonstrate that the g and assay methods
described herein would be tood by one of ordinary skill in the art.
Furter, R., 1998. Expansion of the genetic code: Site-directed p-fluoro-phenylalanine
incorporation in Escherichia coli. Protein Sci. 72419—426.
Merrifield, R.B., Vizioli, L.D., and Boman, H.G. 1982. Synthesis of the antibacterial
peptide cecropin A (1-33). Biochemistry 21: 5020-5031.
Mirmira, R.G., and Tager, HS. 1989. Role of the phenylalanine B24 side chain in
ing insulin interaction with its receptor: Importance of main chain conformation. J Biol.
Chem. 264: 6349-6354.
Sosnick, T.R., Fang, X., and Shelton, V.M. 2000. Application of circular dichroism to
study RNA folding transitions. Methods Enzymol. 317: 393-409.
Wang, Z.X. 1995. An exact mathematical expression for describing competitive biding of
two different s to a protein molecule FEBS Lett. 360: 111-1 14.
Weiss, M.A., Hua, Q.X., Jia, W., Chu, Y.C., Wang, R.Y., and Katsoyannis, PG. 2000.
Hierarchiacal protein sign": insulin's intrachain disulfide bridge tethers a recognition a—
helix. Biochemistry 39: 15429-15440.
Whittaker, J ., and Whittaker, L. 2005. terization of the functional insulin binding
es of the full length insulin receptor. J Biol. Chem. 280: 20932-20936.
Xie, J. and Schultz, PG. 2005. An expanding c code. Methods. 36: 227—23 8.
Claims (20)
1. A ceutical formulation comprising insulin having a variant insulin B-chain ptide containing an ortho-monofluoro-Phenylalanine substitution at position B24 in relation to the sequence of human insulin, in combination with a substitution of an amino acid containing an acidic side chain at position B10 in relation to the sequence of human insulin selected from Aspartic Acid and Glutamic Acid, and a substitution at position B29 in relation to the sequence of human insulin, the substitution being selected from the group consisting of Glutamic Acid, Alanine, Norleucine, Aminobutyric acid, Aminopropionic acid, ne, Diaminobutyric acid, and Diaminopropionic acid, wherein the insulin is present at a concentration of between 0.6 mM and 3.0 mM.
The pharmaceutical formulation of claim 1, wherein the insulin is present at a tration of at least 2 mM.
The pharmaceutical formulation of claim 2, wherein the substitution at position B29 in relation to the sequence of human n is selected from the group consisting of cine, Aminobutyric acid, Aminopropionic acid, Omithine, Diaminobutyric acid, and Diaminopropionic acid.
The pharmaceutical ation of any one of claims 1—3, wherein the variant B chain additionally contains a substitution at position B28 in relation to the sequence of human insulin selected from the group consisting rtic Acid, Proline and Lysine.
The pharmaceutical formulation of any one of claims 1, 2 or 4, wherein the t B chain ns a Glutamic Acid substitution at position B29 in relation to the sequence of human insulin.
The pharmaceutical formulation of any one of claims 1—3, wherein the variant B chain also contains a Lysine substitution at position B3 in relation to the sequence of human insulin.
The pharmaceutical ation of claim6, comprising SEQ ID NO: 8.
The pharmaceutical formulation of any one of claims 1-7, wherein the insulin is an analogue ofa mammalian insulin.
The pharmaceutical ation of claim 8, wherein the mammalian insulin is an analogue of human insulin.
10. The pharmaceutical formulation of claim I, wherein the B—chain polypeptide comprises an acid sequence selected from the group consisting of SEQ ID NOS: 5 and 8 and additionally comprising an A-chain polypeptide sequence having an amino—acid sequence of SEQ ID NO: 9.
ll. The pharmaceutical formulation of any one of claims l—lO, comprising an insulin A- chain polypeptide sequence containing a Glutamic acid substitution at position A8.
12. The ceutical formulation of any one of claims 1-10, comprising an insulin A- chain polypeptide sequence containing a Histidine substitution at position A8.
13. An n analogue or a physiologically acceptable salt thereof, wherein the insulin analogue or a physiologically acceptable salt thereof, wherein the insulin analogue or a physiologically acceptable salt thereof contains a variant B-chain polypeptide incorporating an ortho-monofluoro-Phenylalanine at position B24 and an Aspartic acid or ic acid tution at position B10, and a substitution at position B29 in relation to the sequence of human insulin, the substitution being ed from the group consisting of Glutamic Acid, Alanine, Norleucine, Aminobutyric acid, ropionic acid, Ornithine, Diaminobutryic acid, and opropionic acid, wherein the insulin analogue or a physiologically acceptable salt thereof is present at a concentration of between 0.6 mM and 3.0 mM, for the treatment of elevated blood sugar.
14. The insulin analogue or a physiologically acceptable salt thereof of claim 13, wherein the insulin analogue or a physiologically acceptable salt thereof is present at a concentration of at least 2 mM.
15. The insulin analogue or a logically able salt thereofof claim 13 or 14, wherein the substitution at position B29 in relation to the sequence of human insulin is selected from the group consisting of Norleucine, Aminobutyric acid, Aminopropionic acid, Ornithine, Diaminobutyric acid, and Diaminopropionic acid.
16. The insulin analogue or a physiologically acceptable salt thereof of any one of claims 13- 14, wherein the variant B chain contains a Glutamic Acid substitution at position B29 in relation to the sequence of human insulin.
17. A polypeptide comprising a variant insulin B-chain polypeptide sequence containing an ortho-monofluoro-Phenylalanine substitution at position B24 in relation to the ce of human n, in combination with a substitution of an amino acid containing an acidic side chain at position B10 in on to the sequence of human insulin, and a tution at position B29 in relation to the ce of human n selected from the group consisting of Glutamic Acid, Alanine, Ornithine, Diaminobutyric acid, Diaminopropionic acid, Norleucine, Aminobutyric acid, and Aminopropionic acid.
18. The polypeptide of claim 17, wherein the polypeptide is a proinsulin analogue or single- chain insulin analogue.
19. The polypeptide of claim 17 or claim 18, wherein the polypeptide contains a Glutamic Acid substitution at position B29 in relation to the sequence of human n.
20. The polypeptide of any one of claims 17-19, wherein the polypeptide additionally contains a Lysine substitution at position B3 in relation to the sequence of human insulin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552246P | 2011-10-27 | 2011-10-27 | |
US61/552,246 | 2011-10-27 | ||
PCT/US2012/062423 WO2013063572A1 (en) | 2011-10-27 | 2012-10-29 | Ultra-concentrated rapid-acting insulin analogue formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ624493A NZ624493A (en) | 2016-02-26 |
NZ624493B2 true NZ624493B2 (en) | 2016-05-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9908925B2 (en) | Ultra-concentrated rapid-acting insulin analogue formulations | |
US8343914B2 (en) | Fibrillation resistant proteins | |
US9758563B2 (en) | Insulin analogues with chlorinated amino acids and nucleic acids encoding the same | |
US8399407B2 (en) | Non-standard insulin analogues | |
US9388228B2 (en) | Halogen-stabilized insulin | |
US10745458B2 (en) | Non-standard insulin analogues | |
US20150299286A1 (en) | Glutamic acid-stabilized insulin analogues | |
MX2012009618A (en) | Long-acting insulin analogue preparations in soluble and crystalline forms. | |
US9200053B2 (en) | Insulin analogues containing penta-fluoro-Phenylalanine at position B24 | |
US20220112262A1 (en) | Rapid-acting insulin analogues of enhanced stability | |
US9725493B2 (en) | N-terminal truncated insulin analogues | |
US10995129B2 (en) | Non-standard insulin analogues | |
AU2013368990B2 (en) | Pharmaceutical composition | |
NZ624493B2 (en) | Ultra-concentrated rapid-acting insulin analogue formulations | |
AU2013237740B2 (en) | Insulin analogues containing penta-fluora-phenyalanine at position B24 |